原发免疫性血小板减少症新药治疗研究进展  

Research progress on new drugs for primary immune thrombocytopenia

作　　者：王晗纯 成娟 WANG Hanchun;CHENG Juan(First School of Clinical Medicine of Lanzhou University,Lanzhou 730000,Gansu Province,China;Department of Hematology,the First Hospital of Lanzhou University,Lanzhou 730000,Gansu Province,China;Department of Hematology,Donggang Branch of the First Hospital of Lanzhou University,Lanzhou 730022,Gansu Province,China)

机构地区：[1]兰州大学第一临床医学院,甘肃兰州730000 [2]兰州大学第一医院血液科,甘肃兰州730000 [3]兰州大学第一医院东岗院区血液科,甘肃兰州730022

出　　处：《世界临床药物》2024年第8期897-902,共6页World Clinical Drug

摘　　要：原发免疫性血小板减少症(primary immune thrombocytopenia,ITP)是一种自身免疫性疾病,其特征为血小板破坏增加和巨核细胞成熟不足。近年来,随着对ITP发病机制的深入研究,脾酪氨酸激酶、布鲁顿酪氨酸激酶、新生儿Fc受体抑制剂、血小板去唾液酸化、B细胞活化因子和经典补体途径相关新药逐渐成为ITP治疗的热点。现就近年来ITP新药研究进展作综述,旨在为今后根据发病机制、经济情况等选择合适的个体化治疗方案提供参考。Primary immune thrombocytopenia(ITP)is an autoimmune disease characterized by increased platelet destruction and inadequate megakaryocyte maturation.In recent years,with the in-depth study of the pathogenesis of ITP,new drugs related to spleen tyrosine kinase,Bruton's tyrosine kinase,neonatal Fc receptor inhibitors,platelet desialylation,B-cell activating factor and classical complement pathway have gradually become the focus of ITP treatment.This article reviewed the research progress on new ITP drugs in recent years,aiming to provide reference for selecting appropriate individualized treatment according to the pathogenesis and economic situation in the future.

关 键 词：原发免疫性血小板减少 酪氨酸酶抑制剂 新生儿Fc受体抑制剂 B细胞活化因子抑制剂 补体抑制剂 

分 类 号：R558.2[医药卫生—血液循环系统疾病]